Overview

• Monash University and oNKo-Innate used CRISPR screening to identify an enzyme-encoding gene that restrains NK cell sensitivity to IL-15.
• Genetic deletion of the gene in human NK cells heightened their response to low IL-15 levels and slowed colorectal tumor growth in preclinical models.
• The enzyme’s druggable profile points to the development of small-molecule inhibitors as a targeted immunotherapy strategy.
• Leveraging the body’s own IL-15 could concentrate NK cell activation within tumors while minimizing systemic side effects.
• Future studies will test combinations with existing immune checkpoint inhibitors to enhance overall therapeutic efficacy.